SCHEMBL4350226

SCHEMBL4350226

COCC1=NN(c2ccc(C)c(C)c2)C(=O)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.45
GAA P10253 7/20 0.45
MEN1 O00255 5/20 0.45
SHMT2 P34897 1/20 0.44
ALDH1A1 P00352 6/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
APP P05067 5/20 0.41
MAPT P10636 7/20 0.41
KDM4E B2RXH2 6/20 0.41
RECQL P46063 1/20 0.41
LMNA P02545 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
TDP1 Q9NUW8 4/20 0.39
HTT P42858 1/20 0.39
CYP1A2 P05177 1/20 0.38
CHRM2 P08172 1/20 0.38
CYP3A4 P08684 1/20 0.38
CHRM1 P11229 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4345389 0.84 SHMT2 (0.63) KMT2AGAAMEN1SHMT2ALDH1A1
SCHEMBL4348251 0.82 APP (0.62) KMT2AGAAMEN1SHMT2ALDH1A1
SCHEMBL4334743 0.82 SHMT2 (0.52) KMT2AGAAMEN1SHMT2ALDH1A1
SCHEMBL4348206 0.81 SHMT2 (0.44) KMT2AGAAMEN1SHMT2ALDH1A1
SCHEMBL17034742 0.80 SHMT2 (0.69) KMT2AGAAMEN1SHMT2ALDH1A1
SCHEMBL4343446 0.78 APP (0.47) KMT2AGAAMEN1ALDH1A1L3MBTL1
SCHEMBL5464637 0.78 SHMT2 (0.44) KMT2AGAAMEN1SHMT2ALDH1A1
SCHEMBL4663211 0.77 MAPT (0.63) KMT2AGAAMEN1ALDH1A1L3MBTL1
SCHEMBL29546133 0.77 MAPT (0.63) KMT2AGAAMEN1ALDH1A1L3MBTL1
SCHEMBL4620529 0.77 GAA (0.55) KMT2AGAAMEN1SHMT2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK KMT2A 1838/4885GAA 2853/4885MEN1 229/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK KMT2A 1838/4885GAA 2853/4885MEN1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.